LAKE ZURICH, Ill.– Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers.
Epinephrine Injection, USP is a prescription medicine used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock; for emergency treatment of allergic reactions, including anaphylaxis; and for induction and maintenance of mydriasis during intraocular surgery.
“Fresenius Kabi is pleased to offer Epinephrine Injection to our U.S. customers, further demonstrating our continued commitment to providing quality, cost-saving treatment options to clinicians and the patients they serve in line with #FutureFresenius,” said Arunesh Verma, president, Fresenius Kabi Region U.S. and Member, Executive Leadership Team, Fresenius Kabi AG.
Fresenius Kabi has invested nearly $1 billion to expand and update its U.S. pharmaceutical production and distribution facilities. Fresenius Kabi is committed to domestic production. More than 70 percent of the product units Fresenius ships in the U.S. are drugs listed on the FDA’s Essential Medicines List.
INDICATIONS AND USAGE
Epinephrine is a non-selective alpha- and beta-adrenergic agonist indicated:
- To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
- For emergency treatment of allergic reactions (Type 1), including anaphylaxis.
- For induction and maintenance of mydriasis during intraocular surgery.
